CapitalStars Financial Research Pvt Ltd

CapitalStars

CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of providing fair and accurate trading and investment calls in share and commodity market.we specialize in thorough fundamental and technical research analysis in equity and commodity market to provide best equity and commodity tips to traders and investors.we provide intraday as well as delivery stock tips in NSE and BSEand commodity tips in MCX and NCDEX. Read More

Commodity Market Services

Commodity Market Services

In this service we provide 3-4 intraday calls in MCX with a high level of accuracy. The calls are given in Precious Metals, Base Metals and Energies. You can also avail Free Tips for two days to test our accuracy and if satisfied you can join the services with Capital Stars. Read More

Nifty Market Services

Nifty Future Services

We provide you around 1-2 nifty calls, Bank Nifty Futures, nifty futures tips, sgx nifty tips Daily. You can gain more profit, Get 2 days free trial calls. Read More

Equity Market Services

Equity Market Services

In this service we provide 2-4 intraday stock cash calls in NSE/BSE with a high level of accuracy.You can also avail Free Stock Tips for two days to test our accuracy and if satisfied you can join stock cash services with Capital Stars. Read More

Register now

CapitalStars provides Free Trial in Intraday as well as in Positional Services of Equity, Derivatives, and Commodities and Forex Markets. We provide recommendations in NSE, BSE, MCX, NCDEX, and MCX-SX etc. We render you enough entry and exit time in our calls so clients can easily maximize their profits. Read More

Monday, 7 August 2017

Wockhardt receives USFDA approval for antibiotic injection: 7 Aug 2017



Wockhardt has received approval from the United States Foods &Drugs Administration (USFDA) for an ANDA for 1gm, 2 gm injections of Oxacillin.

Oxacillin is a penicillinase-resistant beta-lactam antibiotic and is used to treat many different infections caused by penicillinase-resistant Staphylococcal and other bacterial injections such as Urinary Tract Infections, Septicemia, Wound Infection, Bacterial meningitis etc.

Wockhardt is expected to launch this product in the United States soon. The product is being manufactured at a contract manufacturing facility based near Milan, Italy.

On the financial front, Wockhardt’s consolidated revenue declined to Rs 891 crore in Q1FY18 on YoY basis. It has reported net loss of Rs 463 crore in Q1FY18 vs net profit of Rs 15.9 crore in Q1FY17.

 Stock View:

 Wockhardt Ltd is currently trading at Rs 605.6, up by Rs 5.6 or 0.93% from its previous closing of Rs 600 on the BSE.

 The scrip opened at Rs 600 and has touched a high and low of Rs 611.3 and Rs 600 respectively. So far 201056(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 6630.48 crore.

 The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 1026.45 on 04-Aug-2016 and a 52 week low of Rs 555 on 22-Jun-2017. Last one week high and low of the scrip stood at Rs 622 and Rs 579.1 respectively.

 The promoters holding in the company stood at 74.15 % while Institutions and Non-Institutions held 6.61 % and 19.13 % respectively.

 The stock is currently trading below its 200 DMA.
Capitalstars Financial Research Private Limited is a research house and an investment advisory carrying out operations in the Indian Equities and Commodity market.We also provide 2 days free trial to our client.Join our services and trade with us. 

Get more details here:-

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
* CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)